制酸劑市場 - 按藥物類別（質子幫浦抑制劑、酸中和劑、抗幽門螺旋桿菌藥物）、適應症（胃食道逆流、胃灼熱、胃炎）、劑量、給藥途徑、配銷通路-全球預測（2024 - 2032）

由於配方和給藥方法的進步，2024 年至 2032 年間，全球制酸劑市場規模將以 5.1% 的複合年成長率擴大。咀嚼片、即溶粉劑和方便的液體形式等創新增強了制酸劑的有效性和使用者體驗。此外，人們對消化系統健康的認知不斷提高，消化系統疾病的發生率也越來越高，促使消費者尋求有效的非處方解決方案。技術進步和健康意識增強相結合，促進了對多樣化和先進抗酸產品的需求不斷成長，推動了市場擴張。

例如，2024年6月，Akums Drugs & Pharmaceuticals Ltd.推出了一款含有海藻酸鈉和碳酸氫鉀的新型抗反流咀嚼片，該片劑已獲得印度藥品監管總局（DCGI）的批准。這項創新反映了制酸劑配方的不斷進步，滿足了對有效、方便用戶使用的消化解決方案日益成長的需求。這項批准凸顯了監管機構對新型抗酸產品的支持不斷增加，而此類先進配方的推出可以透過提供增強的緩解方案和擴大全球消費者的選擇來推動市場成長。

制酸劑產業根據藥物類別、適應症、劑量、給藥途徑、配銷通路和地區而分散。

由於酸中和劑在緩解胃灼熱和胃酸消化不良方面的即時效果，到 2032 年，酸中和劑市場將顯著成長。這些產品包括碳酸鈣和氫氧化鎂，透過直接中和胃酸發揮作用，從而快速緩解症狀。它們在櫃檯上廣泛銷售，並被消費者接受為消化不適的快速解決方案，這有助於它們佔據市場主導地位。胃食道逆流（GERD）的日益普及進一步增加了對酸中和劑的需求。

由於胃灼熱在成年人中廣泛發生，到 2032 年，胃灼熱細分市場將顯著改善。胃灼熱通常由胃食道逆流症 (GERD) 引起，這推動了對可快速有效緩解症狀的非處方制酸劑的巨大需求。片劑、液體劑和咀嚼片等各種配方的推出滿足了不同消費者的喜好，進一步促進了市場成長。此外，人們對控制胃灼熱症狀的認知的提高和自我藥療的便利性也有助於該細分市場的主導地位。

由於該地區消化系統疾病的高發生率和醫療保健意識的不斷增強，亞太地區制酸劑市場佔有率從 2024 年到 2032 年將經歷顯著的複合年成長率。快速的城市化、飲食習慣的改變和壓力水平的增加導致中國和印度等國家胃灼熱和胃酸倒流的發病率上升。此外，不斷擴大的中產階級人口和醫療保健產品的普及正在推動制酸劑的需求。該地區日益關注消化系統健康管理，有效地使亞太地區成為制酸劑產業的重要貢獻者。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 胃腸道疾病盛行率上升
    • 飲食和生活方式的改變
    • 提高意識和自我藥療
    • 製藥進步
  • 產業陷阱與挑戰
    • 副作用和健康風險
    • 替代品的可用性
• 成長潛力分析
• 技術景觀
• 監管環境
• 2023 年定價分析
  • 按地區
  • 按關鍵人物
• 未來市場趨勢
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按藥物類別，2021 - 2032 年

• 主要趨勢
• 質子幫浦抑制劑
• 酸中和劑
• 抗幽門螺旋桿菌藥物
• H2拮抗劑
• 促動力劑
• 前列腺素類似物
• 其他藥物類別

第 6 章：市場估計與預測：按指標分類，2021 - 2032 年

• 主要趨勢
• 胃食道逆流疾病
• 胃灼熱
• 消化不良
• 胃炎
• 消化性潰瘍病
• 其他適應症

第 7 章：市場估計與預測：按劑量，2021 - 2032

• 主要趨勢
• 平板電腦
• 液體
• 其他劑量

第 8 章：市場估計與預測：按管理途徑，2021 - 2032 年

• 主要趨勢
• 口服
• 可注射

第 9 章：市場估計與預測：按配銷通路，2021 - 2032

• 主要趨勢
• 醫院藥房
• 網路藥房
• 零售藥房

第 10 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 11 章：公司簡介

• Aurobindo Pharma Limited
• Bayer AG
• Bristol Myers Squibb Company
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• F. Hoffmann-La Roche Ltd.
• Gsk plc
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd
• The Procter & Gamble Company
• Viatris Inc.

Global Antacids Market size will expand at a 5.1% CAGR between 2024 and 2032, attributed to advances in formulation and delivery methods. Innovations such as chewable tablets, fast-dissolving powders, and convenient liquid forms enhance the effectiveness and user experience of antacids. Furthermore, greater awareness about digestive health and the heightened rate of digestive disorders encourages consumers to seek effective over-the-counter solutions. This combination of technological improvements and increased health consciousness contributes to a rising demand for diverse and advanced antacid products, fueling market expansion.

For instance, in June 2024, Akums Drugs & Pharmaceuticals Ltd. launched a new anti-reflux chewable tablet containing sodium alginate and potassium bicarbonate, which has been approved by the Drugs Controller General of India (DCGI). This innovation reflects growing advancements in antacid formulations, catering to the increasing demand for effective, user-friendly digestive solutions. The approval highlights the rising regulatory support for new antacid products, while the introduction of such advanced formulations can drive market growth by offering enhanced relief options and expanding consumer choice globally.

The antacids industry is fragmented based on drug class, indication, dosage, route of administration, distribution channel, and region.

The acid neutralizers segment will observe a noteworthy surge through 2032, spurred by their immediate effectiveness in relieving heartburn and acid indigestion. These products, which include calcium carbonate and magnesium hydroxide, work by directly neutralizing stomach acid, providing rapid symptom relief. Their widespread availability over the counter and acceptance by consumers as a quick solution for digestive discomfort contribute to their dominant market position. The growing prevalence of gastroesophageal reflux disease (GERD) further boosts the demand for acid neutralizers.

The heartburn segment will undergo a remarkable upturn by 2032, owing to the widespread occurrence of this condition among adults. Heartburn, often caused by gastroesophageal reflux disease (GERD), drives a significant demand for over-the-counter antacids that provide quick and effective relief. The availability of various formulations, such as tablets, liquids, and chewables, caters to diverse consumer preferences, further boosting market growth. Also, increasing awareness about managing heartburn symptoms and the convenience of self-medication contribute to the segment's dominance.

Asia Pacific antacids market share will experience a notable CAGR from 2024 to 2032 due to the region's high prevalence of digestive disorders and growing healthcare awareness. Rapid urbanization, changing dietary habits, and increased stress levels contribute to the rising incidence of heartburn and acid reflux in countries like China and India. Besides, the expanding middle-class population and improved access to healthcare products are driving the demand for antacids. The region's growing focus on managing digestive health effectively positions Asia Pacific as a crucial contributor to the antacids industry.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of gastrointestinal disorders
    • 3.2.1.2 Dietary and lifestyle changes
    • 3.2.1.3 Increased awareness and self-medication
    • 3.2.1.4 Pharmaceutical advancements
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects and health risks
    • 3.2.2.2 Availability of substitutes
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Pricing analysis, 2023
  • 3.6.1 By region
  • 3.6.2 By key player
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Proton pump inhibitors
• 5.3 Acid neutralizers
• 5.4 Anti-H.pyloric drugs
• 5.5 H2 antagonists
• 5.6 Pro-motility agents
• 5.7 Prostaglandin analogous
• 5.8 Other drug classes

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Gastroesophageal reflux disease
• 6.3 Heartburn
• 6.4 Indigestion
• 6.5 Gastritis
• 6.6 Peptic ulcer disease
• 6.7 Other indications

Chapter 7 Market Estimates and Forecast, By Dosage, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Tablets
• 7.3 Liquid
• 7.4 Other dosages

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Injectable

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacy
• 9.3 Online pharmacy
• 9.4 Retail pharmacy

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Aurobindo Pharma Limited
• 11.2 Bayer AG
• 11.3 Bristol Myers Squibb Company
• 11.4 Cipla Limited
• 11.5 Dr. Reddy's Laboratories Ltd.
• 11.6 F. Hoffmann-La Roche Ltd.
• 11.7 Gsk plc
• 11.8 Hikma Pharmaceuticals PLC
• 11.9 Lupin Limited
• 11.10 Novartis AG
• 11.11 Pfizer Inc.
• 11.12 Sun Pharmaceutical Industries Ltd
• 11.13 Teva Pharmaceutical Industries Ltd
• 11.14 The Procter & Gamble Company
• 11.15 Viatris Inc.